Search for:

In brief

In December 2022, the Health Sciences Authority (HSA) detected potent ingredients in products marketed for young children and alerted the public against purchasing them. The HSA also published information on a retail-level recall in respect of an oral solution.


Key takeaways

  • Sellers and suppliers should note that health products must be in line with applicable healthcare regulations. The HSA will not hesitate to publish information on adverse effects of health products or on retail-level recalls.
  • Anyone who sells or supplies adulterated health products may be imprisoned for up to three years and/or fined up to SGD 100,000 upon conviction. Anyone who sells or supplies unwholesome health products may be imprisoned for up to two years and/or fined up to SGD 50,000 upon conviction.

In depth

Following serious medical conditions experienced by a four-year-old child after use of a rash cream, the HSA conducted an analysis of the product. The analysis revealed that the rash cream was falsely labelled and contained four potent medicinal ingredients including two steroids. The rash cream, which was sold by a local peddler at a makeshift stall, was also marketed on local e-commerce platforms. The HSA has since worked with various e-commerce platforms to remove the product listings.

Separately, the HSA also published information on a retail-level product recall in respect of a prescription-only medicine. The product recall was issued due to inconsistency of microbial limit findings reported by the manufacturer. Hospitals have been instructed to stop supplying the affected batches of the prescription-only medicine and to return the remaining stocks to the supplier.

Author

Andy Leck is the head of the Intellectual Property and Technology (IPTech) Practice Group and a member of the Dispute Resolution Practice Group in Singapore. He is a core member of Baker McKenzie's regional IP practice and also leads the Myanmar IP Practice Group. Andy is recognised by reputable global industry and legal publications as a leader in his field. He was named on "The A-List: Singapore's Top 100 lawyers" by Asia Business Law Journal 2018. In addition, Chambers Asia Pacific notes that Andy is "a well-known IP practitioner who is highlighted for his record of handling major trade mark litigation, as well as commercial exploitation of IP rights in the media and technology sectors. He's been in the industry for a long time and has always been held in high regard. He is known to be very fair and is someone you would like to be in the trenches with you during negotiations." Furthermore, Asian Legal Business acknowledges Andy as a leading practitioner in his field and notes that he “always gives good, quick advice, [is] client-focused and has strong technical knowledge for his areas of practice.” Andy was appointed by the Intellectual Property Office of Singapore (IPOS) as an IP Adjudicator to hear disputes at IPOS for a two-year term from April 2021. He has been an appointed member of the Singapore Copyright Tribunal since May 2010 and a mediator with the WIPO Arbitration and Mediation Center. He is also appointed as a Notary Public & Commissioner for Oaths in Singapore. He previously served on the International Trademark Association’s Board of Directors and was a member of the executive committee.

Author

Ren Jun Lim is a principal with Baker McKenzie Wong & Leow. He represents local and international clients in both contentious and non-contentious intellectual property matters. He also advises on a full range of healthcare, as well as consumer goods-related legal and regulatory issues. Ren Jun co-leads Baker McKenzie Wong & Leow's Healthcare as well as Consumer Goods & Retail industry groups. He sits on the Law Society of Singapore IP Committee and on the Executive Committee of the Association of Information Security Professionals. He is also a member of the Vaccines Working Group, Singapore Association of Pharmaceutical Industries, a member of the International Trademark Association, as well as a member of the Regulatory Affairs Professionals Association. Ren Jun is ranked in the Silver tier for Individuals: Enforcement and Litigation and Individuals: Prosecution and Strategy, and a recommended lawyer for Individuals: Transactions by WTR 1000, 2020. He is also listed in Asia IP's Best 50 IP Expert, 2020, recognised as a Rising Star by Managing IP: IP Stars, 2019 and one of Singapore's 70 most influential lawyers aged 40 and under by Singapore Business Review, 2016. Ren Jun was acknowledged by WTR 1000 as a "trademark connoisseur who boasts supplementary knowledge of regulatory issues in the consumer products industry." He was also commended by clients for being "very responsive to enquiries and with a keen eye for detail, he is extremely hands-on. His meticulous and in-depth approach to strategising is key to the excellent outcomes we enjoy."